NCT05842174RecruitingPhase 1/2
Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma
Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma Through Image-guided Locoregional Therapy
Source: ClinicalTrials.gov · Last updated 16 Apr 2026
Brief summary (registry, in English)
Trans-arterial chemoembolization (TACE) is the most commonly used therapy for patients with unresectable hepatocellular carcinoma (HCC). TACE is a minimally invasive procedure that involves placing a catheter into the artery in the liver that feeds the tumor, administering chemotherapeutics and then blocking the artery with embolics in order to kill tumor cells by depriving them of essential oxygen and nutrients. While TACE has a proven survival benefit, local recurrence is common, and long-term survival rates are poor. Prior studies demonstrate that HCC cells survive the oxygen and nutrient deprivation through autophagy, a process of cellular self-eating, to provide nutrients required for survival. The proposed project will leverage this dependency to develop a novel approach to TACE that integrates autophagy inhibition to improve therapeutic response by increasing tumor cell killing and enhancing anti-tumor immunity.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 93 (estimated)
- First submitted
- 5 Apr 2023
- Start date
- 1 Apr 2026
- Primary completion date
- 30 Sept 2029
- Lead sponsor
- VA Office of Research and Development
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT05842174
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 93
- From 1 Apr 2026 to the primary completion date, 30 Sept 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior LRT or systemic therapy to the target lesion
- Contraindication to contrast enhanced MRI or metallic implant within the liver.
Other illness
- HCQ allergy, porphyria, uncontrolled psoriasis, and existing retinopathy
- Serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study)
Lab values
- QT prolongation on ECG
- Females who are pregnant or breast feeding at the time of screening will not be eligible for this study
- a serum or urine pregnancy test will be performed in women of child-bearing potential at screening
Other
- Retinopathy on ophthalmologic examination
- Lesion not amenable to biopsy based on pre-TACE imaging as determined by treating interventional radiologist
Who the study is looking for
- Male or female, aged 18 years, meeting criteria for diagnosis of BCLC B HCC and referred to undergo TACE
- HCC measuring 3 cm in minimum transverse diameter and meets LI-RADS 5 criteria based on cross-sectional imaging as determined by a board-certified, sub-specialty trained radiologist
- Childs Pugh Turcotte A/B7, Performance Status 0
- Informed of investigational nature of this study with provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA Coordinator of this site? Confirm its status | Philadelphia | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.